Fibronectin affects transient MMP2 gene expression through DNA demethylation changes in non-invasive breast cancer cell lines

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Pereira, Isabela T ^a   Ramos, Edneia A S ^a   Costa, Erico T ^b   Camargo, Anamaria A ^b   Manica, Graciele C M ^a   Klassen, Liliane M B ^a   Chequin, Andressa ^a   Braun Prado, Karin ^a   Pedrosa, Fábio De O ^a   Souza, Emanuel M ^a   Costa, Fabricio F ^c   Klassen, Giseli ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b HOSPITAL SÍRIO LIBANÊS   (Brazil)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; FIBRONECTIN; GELATINASE A; AZACITIDINE; DECITABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; DNA METHYLATION; ENZYME ACTIVITY; EPIGENETICS; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GENE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; MCF 7 CELL LINE; MMP2 GENE; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; STROMA; TUMOR MICROENVIRONMENT; ANALOGS AND DERIVATIVES; BREAST TUMOR; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TIME; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR INVASION;

AZACITIDINE; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DNA METHYLATION; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PROMOTER REGIONS, GENETIC; TIME FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84930068573     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105806     Document Type: Article

References (42)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA: A cancer journal for clinicians 64: 9-29.
2. INCA (2014) Incidência do câncer no Brasil. Estimativa 2014.
3. Duffy SW (2005) Some current issues in breast cancer screening. Journal of medical screening 12: 128-133.
4. Sethi N, Kang Y (2011) Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nature reviews Cancer 11: 735-748.
5. Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331: 1559-1564.
6. Stamenkovic I (2000) Matrix metalloproteinases in tumor invasion and metastasis. Seminars in cancer biology 10: 415-433.
7. Artacho-Cordon F, Rios-Arrabal S, Lara PC, Artacho-Cordon A, Calvente I, et al. (2012) Matrix metalloproteinases: potential therapy to prevent the development of second malignancies after breast radiotherapy. Surgical oncology 21: e143-e151.
8. Stanton H, Gavrilovic J, Atkinson SJ, d'Ortho MP, Yamada KM, et al. (1998) The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. Journal of cell science 111 (Pt 18): 2789-2798.
9. Mitra A, Chakrabarti J, Banerji A, Das S, Chatterjee A (2006) Culture of human cervical cancer cells, SiHa, in the presence of fibronectin activates MMP-2. Journal of cancer research and clinical oncology 132: 505-513.
10. Das S, Banerji A, Frei E, Chatterjee A (2008) Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life sciences 82: 467-476.
11. Moroz A, Delella FK, Lacorte LM, Deffune E, Felisbino SL (2013) Fibronectin induces MMP2 expression in human prostate cancer cells. Biochemical and biophysical research communications 430: 1319-1321.
12. Chernov AV, Sounni NE, Remacle AG, Strongin AY (2009) Epigenetic control of the invasion-promoting MT1-MMP/MMP-2/TIMP-2 axis in cancer cells. The Journal of biological chemistry 284: 12727-12734.
13. Chik F, Szyf M (2011) Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 32: 224-232.
14. Berger SL (2007) The complex language of chromatin regulation during transcription. Nature 447: 407-412.
15. Wan L, Pantel K, Kang Y (2013) Tumor metastasis: moving new biological insights into the clinic. Nature medicine 19: 1450-1464.
16. Lelievre SA (2009) Contributions of extracellular matrix signaling and tissue architecture to nuclear mechanisms and spatial organization of gene expression control. Biochimica et biophysica acta 1790: 925-935.
17. Ioachim E, Charchanti A, Briasoulis E, Karavasilis V, Tsanou H, et al. (2002) Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. European journal of cancer 38: 2362-2370.
18. Helleman J, Jansen MP, Ruigrok-Ritstier K, van Staveren IL, Look MP, et al. (2008) Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clinical cancer research : An official journal of the American Association for Cancer Research 14: 5555-5564.
19. Carraher CL, Schwarzbauer JE (2013) Regulation of matrix assembly through rigidity-dependent fibronectin conformational changes. The Journal of biological chemistry 288: 14805-14814.
20. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nature reviews Cancer 9: 265-273.
21. Miettinen PJ, Ebner R, Lopez AR, Derynck R (1994) TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. The Journal of cell biology 127: 2021-2036.
22. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. The Journal of clinical investigation 119: 1420-1428.
23. Park J, Schwarzbauer JE (2013) Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene.
24. Tam WL, Weinberg RA (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nature medicine 19: 1438-1449.
25. Hurtubise A, Momparler RL (2006) Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-29-deoxycytidine (decitabine) on human breast carcinoma cells. Cancer chemotherapy and pharmacology 58: 618-625.
26. Ni X, Xia T, Zhao Y, Zhou W, Wu N, et al. (2014) Downregulation of miR- 106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. Cancer science 105: 18-25.
27. Kenny HA, Kaur S, Coussens LM, Lengyel E (2008) The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. The Journal of clinical investigation 118: 1367-1379.
28. Meng XN, Jin Y, Yu Y, Bai J, Liu GY, et al. (2009) Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. British journal of cancer 101: 327-334.
29. Liang CC, Park AY, Guan JL (2007) In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nature protocols 2: 329-333.
30. Mayor R, Munoz M, Coolen MW, Custodio J, Esteller M, et al. (2011) Dynamics of bivalent chromatin domains upon drug induced reactivation and resilencing in cancer cells. Epigenetics : official journal of the DNA Methylation Society 6: 1138-1148.
31. Kagey JD, Kapoor-Vazirani P, McCabe MT, Powell DR, Vertino PM (2010) Long-term stability of demethylation after transient exposure to 5-aza-29- deoxycytidine correlates with sustained RNA polymerase II occupancy. Molecular cancer research: MCR 8: 1048-1059.
32. Rothbart SB, Strahl BD (2014) Interpreting the language of histone and DNA modifications. Biochimica et biophysica acta.
33. Rose NR, Klose RJ (2014) Understanding the relationship between DNA methylation and histone lysine methylation. Biochimica et biophysica acta.
34. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, et al. (2006) Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer research 66: 3541-3549.
35. Voigt P, Tee WW, Reinberg D (2013) A double take on bivalent promoters. Genes & development 27: 1318-1338.
36. Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, et al. (2013) Architecture of epigenetic reprogramming following Twist1-mediated epithelialmesenchymal transition. Genome biology 14: R144.
37. McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, et al. (2008) Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer research 68: 5753-5759.
38. Pryzbylkowski P, Obajimi O, Keen JC (2007) Trichostatin A and 5 Aza-29 deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Res Treat 111: 15-25.
39. Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID, et al. (2009) Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC cancer 9: 20.
40. Kleiner DE, Stetler-Stevenson WG (1994) Quantitative zymography: detection of picogram quantities of gelatinases. Analytical biochemistry 218: 325-329.
41. Leber TM, Balkwill FR (1997) Zymography: A single-step staining method for quantitation of proteolytic activity on substrate gels. Analytical biochemistry 249: 24-28.
42. Ivascu A, Kubbies M (2007) Diversity of cell-mediated adhesions in breast cancer spheroids. International journal of oncology 31: 1403-1413.